Synaptic proteins in CSF relate to Parkinson's disease stage markers.
Synaptic proteins in CSF relate to Parkinson's disease stage markers.
复制标题
DOI：
10.1038/s41531-017-0008-2
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Aarsland D
中科院分区：
文献类型：
--
作者：
Bereczki E;Bogstedt A;Höglund K;Tsitsi P;Brodin L;Ballard C;Svenningsson P;Aarsland D
最近对帕金森病大脑形态和功能变化的研究发现，突触形成发生了改变，但它们在认知能力下降中的作用仍然是一个正在探索的领域。在这里，我们通过酶联免疫吸附测定测量了 139 名参与者（87 名对照者和 52 名帕金森病患者，其中 30 名未接受过药物治疗）的脑脊液中三种关键突触蛋白 Rab3A、SNAP25 和神经粒蛋白的浓度，并探讨了它们与运动和认知症状的关系。探讨了与运动疾病阶段（通过 Hoehn 和 Yahr 量表评估）和认知表现（通过蒙特利尔认知评估分数评估）的关联。帕金森病患者中 SNAP25 浓度总体升高 (p = 0.032)。在未接受药物治疗的患者亚组中发现神经颗粒素水平升高（p = 0.023）。在完全帕金森病组 (p = 0.017)、未用药组 (p = 0.021) 和运动疾病阶段 (p = 0.041) 中，神经颗粒素浓度增加与认知障碍之间观察到显着相关性。 Rab3a 浓度没有观察到明显的疾病驱动变化。帕金森病患者脑脊液中 SNAP25 和神经粒蛋白的浓度以疾病特异性的方式增加，并且与认知和运动症状的严重程度相关。未来的纵向研究应探讨脑脊液突触蛋白是否可以预测帕金森病的认知能力下降。脑脊液 (CSF) 中突触蛋白的水平与帕金森病 (PD) 的严重程度相关。神经细胞之间的通讯功能障碍是早期帕金森病和其他神经退行性疾病的既定标志。由于各个大脑区域的突触丢失，突触蛋白会渗入脑脊液，但人们对其浓度与疾病阶段和预后的关系知之甚少。瑞典卡罗林斯卡学院的 Erika Bereczki 及其同事测量了 52 名 PD 患者和 87 名对照者脑脊液中三种突触蛋白的浓度。他们发现其中两种物质（神经粒蛋白和 SNAP25）的水平与运动和非运动症状的严重程度相关。进一步的工作将确定这些蛋白质是否有助于帕金森病的早期检测并帮助预测疾病进展。
Recent findings of morphological and functional changes in Parkinson’s disease brains have shown altered synapse formation, but their role in cognitive decline is still an area under exploration. Here we measured the concentration of three key synaptic proteins, Rab3A, SNAP25 and neurogranin by enzyme-linked immunosorbent assay, in cerebrospinal fluid from a total of 139 participants (87 controls and 52 Parkinson’s disease patients out of which 30 were drug-naïve) and explored their associations with motor and cognitive symptoms. Associations with motor disease stage (assessed by Hoehn and Yahr scale) and cognitive performance (assessed by the Montreal Cognitive Assessment scores) were explored. An overall increase in the concentration of SNAP25 was found in Parkinson’s disease patients (p = 0.032). Increased neurogranin levels were found in the drug naïve patients subgroup (p = 0.023). Significant associations were observed between increased concentration of neurogranin and cognitive impairment in total Parkinson’s disease group (p = 0.017), as well as in the drug naïve (p = 0.021) and with motor disease stage (p = 0.041). There were no significant disease-driven changes observed in the concentration of Rab3a. Concentrations SNAP25 and neurogranin were increased in cerebrospinal fluid of Parkinson’s disease patients in a disease specific manner and related to cognitive and motor symptom severity. Future longitudinal studies should explore whether cerebrospinal fluid synaptic proteins can predict cognitive decline in Parkinson’s disease. The levels of synaptic proteins in the cerebrospinal fluid (CSF) correlate with Parkinson’s disease (PD) severity. Dysfunctional communication between nerve cells is an established hallmark of early stage PD and other neurodegenerative disorders. As synapses are lost from various brain areas synaptic proteins leak into the CSF, but little is known about how their concentration correlates with disease stage and prognosis. Erika Bereczki and colleagues at the Karolinska Institutet in Sweden measured the concentration of three synaptic proteins in the CSF of 52 patients with PD and 87 controls. They found that the levels of two of them (neurogranin and SNAP25) correlated with the severity of both motor and non-motor symptoms. Further work will determine whether these proteins could aid early detection of PD and help predict disease progression.